by a cap-snatching mechanism. The polymerase complex also catalyses the genome replication, generating a positive-sense complementary RNA (cRNA), a replicative intermediate that serves as a template for the synthesis of more copies of the viral genomic segments (vRNA). [33, 34, 42, 43] The polymerase catalytic site is in PB1; PB2 includes the capped-RNA recognition domain, required for generation of the primer for transcription, while PA is involved in the complex assembly. [42, [44] [45] [46] Only if correctly assembled RdRp can work and the virus can replicate its genome. [41, 44, 47, 48] Indeed, even if so far the search for new antiviral targets has been mostly focused on the PA endonuclease active site, PB2 cap-binding domain and PB1 subunit, [49] a very attractive strategy could be the disruption of RdRp complex assembly through proteinprotein interaction (PPI) inhibition. In fact, PPIs represent crucial events in many biological processes under both physiological and pathological conditions. In particular, crystallization studies have revealed that PA-PB1 interaction may be a very promising druggable target, [29, [49] [50] [51] [52] because of the high degree of conservation of several interface residues among FluA, FluB and FluC, [27, 53, 54] that suggests that its inhibitors may be active against many viral subtypes and less prone to drug-resistance, and because of the little size of the specific interface that allows small with ELISA evaluation revealed the 3-cyano-4,6-diphenyl-pyridine scaffold as a promising potential inhibitor of the PA−PB1 complex by mimicking the hydrophilic N-terminal portion of PB1 (residues 1−4) and the most important interactions with the C-terminal domain of PA. Compounds 3 and 4 (Figure 1) , showed the best activity profile. [63] The following validation of the reliability of the old homology model was performed through comparison with the more complete X-ray structure of FluA H17N10 RdRp (PDB ID: 4WSB) [41] and the superposition in the PB1-binding site region. [71] Chemical modifications aided by molecular modeling studies allowed us to make preliminary SAR considerations and to identify some compounds (5 and 6, Figure   1 ) as promising anti-flu agents, even if they suffer from low water solubility that implied the design and validation of a new serum-free ELISA. [71] 63, 66, 67, 71] DISCUSSION. The biological evaluation of the compounds described above [71] allowed us to confirm this novel class of diphenyl-pyridine derivatives as promising and non-toxic PA-PB1 disrupting RdRp inhibitors, and to determine preliminary SARs. In order to increase the affinity to the PB1 binding site, a rational design of new derivatives was performed.
As already discussed, this library of derivatives contains a scaffold that directly competes and displaces the Nterminal portion of PB1 (PB1N). Indeed, the overlap of PB1N in the X-ray crystallography structure with the docking pose of compound 3 (Figure 2) revealed that the cyano-pyridine core fits very well with a central region of PB1N, but the compound fails in establishing crucial interactions instead made with PA by the three terminal amino acids (Met1-Asp2-Val3) of PB1N peptide. [63, 71] With the aim to enhance the ability of our compounds to completely displace PB1 and increase their affinity toward the target protein PA, a hybrid derivative, combining the cyano-pyridine core linked to the PB1N last peptide side chain (Met-Asp-Val) has been designed and docked into the PB1 binding site on PA. The rational design was performed choosing the cyano-pyridine ring of compound 3 as the nucleus to which specific amino acids were added on the C2 side chain. Since the majority of the first virtual screening hits [63] were characterized by a p-methyl group substituent on the C4 phenyl ring, this was maintained.
At first, the hybrid Target Compound (see structure in Scheme S1 of Supplementary information) was planned with the molecule bearing the peptide as N-terminal amine. Despite a lot of attempts (some of which are reported in Supplementary information), the synthesis of this first designed Target Compound has proven to be difficult to achieve; so we decided to prepare its "inverted amide", inserting the peptide as C-terminal.
This modification was shown to be not relevant for the interaction with the most important residues of PA, confirming a sufficiently similar docking pose.
In fact, from docking simulations, emerged that both the first designed Target Compound and the compound with the inverted amide 11 (structure reported in The adducts with valine, valine-aspartate and valine-aspartate-methionine methyl esters (7a, 9 and 11 respectively, shown in Figure 4 ) were synthesized in order to explore the chemical space around the C2 side chain. We decided to introduce amino acids as esters because they are more permeable through membranes than the correspondent free acids. [72, 73] Compound 11 turned out to be a weak inhibitor, while more interesting activity profiles have been revealed for compounds 7a and 9. They showed a relevant discordance between the low PA-PB1 interaction inhibition and the good intracellular activity, but minireplicon assays confirmed the on-target activity (data reported in Table 1 ), suggesting a possible enzymatic hydrolysis in the cell. To confirm this hypothesis, the free acid of Val and Val-Asp adducts were synthesized, through a controlled hydrolysis in basic conditions, yielding 8 and 10 respectively. The biological data of these derivatives seem to confirm that they are the actual responsible for the antiviral activity, as expected. The good results of Val adducts 7a and 8 are in agreement with experimental data previously reported by Wunderlich et al [74] that revealed Val3 on the PB1 peptide as one of the most important residues for the interaction with PA, exhibiting the lowest binding free energy, [63] thus suggesting that its displacement could inhibit the RdRp heterodimerization.
Encouraged by these findings, we decided to investigate the effects of other amino acids at the protein-protein surface of the target through the addition of different L-amino acids as methyl esters (Leu, Ile, His, Arg, Phe, Tyr, Glu: compounds 7b-h), whose structures are reported in Figure 4 , through the validate synthetic procedure of 7a (Scheme 2). Leucine (7b) and isoleucine (7c) have been chosen as hydrophobic good replacement of valine, while the other residues have been selected as representatives of all the existing classes of amino acids to investigate about the possible interactions of their different functions. Histidine (7d) and arginine (7e) bear a positive charge at physiological pH, phenylalanine (7f) and tyrosine (7g) are characterized by aromatic lateral chains that can interact with the protein region I and glutamate (7h), if hydrolysed, bears negative charges that could enhance the affinity of ligands towards the protein. Molecular docking studies were then carried out to investigate the possible binding mode of these molecules within the PB1 binding site of PA, while molecular dynamics (MD) simulations were performed to identify the molecular determinants responsible for in vitro PA-PB1 PPI inhibition. CHEMISTRY. The first part of the synthetic work has been devoted to the set-up of a fast and high yielding procedure for the preparation of the 4, To synthesize the mono amino acid adducts 7a-h, we used the same amidation procedure with EDC (1-ethyl-3-(3-dimethylaminopropyl)carbodiimide) and HOBt (hydroxybenzotriazole) as coupling agents [78] and racemization suppressors, [80] The synthetic route to obtain di-amino acid adduct 9 is shown in Scheme 3. The Val-Asp dipeptide 16 was synthesized in solution phase through the previous described amidation procedure with Fmoc-L-valine and Laspartic acid methyl ester. Dipeptide 16 was subjected to the cleavage of the Fmoc protecting group with sodium azide (NaN3). The free amine 17 was then coupled with acid derivative 15 furnishing the di-amino acid adduct 9. Eventually, the ester functions of 9 were hydrolysed by using a sodium hydroxide solution affording the bicarboxylic acid derivative 10. Scheme 3. Synthesis of di-amino acid adducts 9 and 10. Reagents and conditions: (i) EDC, HOBt, dry DIPEA, dry DMF, N2, 0 °C to r.t., 8 h; (ii) NaN3, DMF, 50 °C, 5 h; (iii) EDC, HOBt, dry DIPEA, dry DMF, N2, 0°C to r.t., 4 h; (iv) NaOH 1N, THF/EtOH/H2O, r.t., 30 min.
The synthesis of the tri-amino acid adduct 11 required the preparation of the tripeptide Val-Asp-Met, that was performed in solid phase through the Fmoc strategy and is reported in Scheme 4. MW-SPPS (Microwave Solid Phase Peptide Synthesis) was conducted by using an automated peptide synthesizer, that was charged with a resin (Wang resin) bearing the last amino acid of our tripeptide, L-methionine, covalently linked. Prior to use, the resin was swallowed for 2 hours in DMF. In addition to resin and solvents (DMF and DCM), the instrument was also charged with the other two protected amino acids (Fmoc-L-Asp-(OtBu) and Fmoc-L-Val), the coupling activators (HOBt and HBTU), a base (DIPEA) and a deprotection solution (20% piperidine in DMF).
At the end of the deprotection and coupling cycles, we obtained the resin-bounded tripeptide 18, which was manually cleaved to avoid the employment of corrosive trifluoroacetic acid (TFA) inside the instrument. The cleavage of the resin was performed through a solution of TFA, H2O and triisopropylsilane (TIPS) as scavengers for the reactive species produced during resin cleavage, and dithiotreithol (DTT) to avoid methionine oxidation. Under these acid conditions the tert-butyl ester in the aspartate lateral chain was hydrolysed furnishing the resin-free tripeptide 19 which was used in the next step without further purification.
Then the methyl esterification of dicarboxylic functions of 19, accomplished by treating it with a methanolic solution of freshly distilled thionyl chloride (SOCl2), was necessary to avoid side reactions in next steps. The reaction was carried out at room temperature and with controlled equivalents of SOCl2 in order not to allow the acid-catalysed racemization of the methionine stereocenter. Dimethyl ester tripeptide 20 was then deprotected from the Fmoc group furnishing the free amine 21 which was coupled with carboxylic core 15 affording the final tri-amino acid adduct 11. Moreover, to confirm the mechanism of action implied by the ELISA interaction assay, the ability of the most interesting compounds (7a, 7c, 8, 9, 15, 24) to inhibit FluA RdRp enzymatic activity in a cellular context was assessed by minireplicon assays in transfected HEK 293T cells, using ribavirin (RBV) [81] as a reference drug, since it acts as RNA synthesis inhibitor thanks to its guanosine-like structure. In Table 1 all the biological data are reported.
The tripeptide derivative (11) showed a weak inhibitory activity (IC50 = 68±14 µM) but such an activity is not retained in cells (EC50 > 100 µM in PRA).
The biological data for the methyl esters 9 and 7a, in particular the minireplicon assay results for 7a, confirmed our hypothesis of a possible intracellular hydrolysis, so one could assume that their actual target is the PA-PB1 interaction, considering similar or lower EC50 values in minireplicon assays when compared to the ones observed in PRAs.
In fact, the free acid adduct 10 inhibited the interaction between PA and PB1 with a IC50 value of 77±9 µM, while it was less active in blocking viral replication in infected cells (EC50 = 100 µM in PRA), likely due to its inability to pass through the membranes. In contrast, the correspondent methyl ester 9 exhibited a good activity in cell, according to PRA and minireplicon results (EC50 = 49±8 µM and EC50 = 59±18 µM, respectively), but a low ability to disrupt the PA-PB1 interaction in ELISA (IC50 = 143±1 µM).
As far as the valine adducts, the methyl ester derivative 7a seemed to have a similar biological profile than the di-peptide adduct 9, showing a good antiviral activity (EC50 = 52±2 µM in PRA) and confirming the on-target activity in minireplicon assays (EC50 = 41±16 µM), while a high IC50 value of 167±20 µM was detected. The free acid derivative 8 showed similar EC50 values in PRA and in minireplicon experiments (50±7 and 77±14 µM, respectively) and a more potent activity in ELISA (IC50 = 76±16 µM) when compared to its methyl ester correspondent 7a.
Surprisingly, although the small difference in the side chain, leucine (7b) and isoleucine (7c) adducts were found to have very different biological profiles: 7b appeared to have a low ability to disrupt the PA-PB1 interaction (IC50=149±15 µM), but showed a weak inhibitory activity in infected cells (EC50 = 97±9 µM; while 7c had a very promising antiviral activity in infected cells (EC50 = 39±2 µM in PRA) and likely acted by inhibiting the PA-PB1 PPI, as suggested by both the ELISA (IC50 = 36±3 µM) and the minireplicon assays (EC50 = 53±16µM). The histidine derivative (7d) resulted to have good activity in the ELISA experiments (IC50 = 32±7 µM), but, unfortunately, a high cytotoxicity was detected (CC50 = 152±3 µM in MDCK cells). The arginine and the tyrosine adducts (7e and 7g respectively) were effective as disruptors of the target interaction, with IC50 values of 48±8 and 18±5 µM, respectively, but did not retain the antiviral activity in cells (EC50 > 100 µM). A particular case is the one of the phenylalanine derivative (7f) that seems not to have affinity with PA (IC50> 200 µM), but in infected cells was active with an EC50 value of 68±10 µM in PRA, perhaps after the ester hydrolysis or through an off-target mechanism of action. At the end, the glutamate derivative (7h) is found to be inactive.
All tested compounds were non cytotoxic in MDCK and HEK 293T cells (CC50 > 200 µM) apart from 7d.
Comparing our best compound (7c) to the previous published compound 5, we can observe a similar ability to disrupt the PA-PB1 interaction in ELISA. Moreover, even if compound 5 is a very potent antiviral agent with an EC50 of 9.2±0.7 µM in PRA, its activity is probably due to other additional modes of action as revealed by minireplicon assays (EC50 = 86.6±15 µM).
The intermediates 15, 23, 24 (the structures of the two last compounds are reported in Supplementary Information) were also tested: while the amine 23 resulted inactive, the acid 15 and the amide 24 showed interesting activity profiles, even if a low toxic behaviour in HEK 293T cell line was detected. 
MOLECULAR MODELING.
The ELISA PA−PB1 interaction assay provided a direct measure of the PA-PB1 PPI inhibition by test compounds. Here, to add further insights into the inhibition mechanism, we carried out molecular modeling investigations. First, the possible binding mode of compounds listed in Table 1 to the PB1 binding site of PA was predicted by molecular docking, which was performed with the GOLD program (GoldScore function) [82] according to previous works. [63, 71] Notably, all compounds and intermediates showed to fit the PB1 site of PA with a binding geometry that is highly comparable each other, as well as to the binding mode already described above for compound 11 and the reference inhibitor PB1N (see Figure 2 and Figure 3) . The binding mode of tested compounds is described in Supplementary information. However, probably because of the narrow activity range observed in the ELISA assay ( Table 1) , any attempt to correlate the ligands' scores with experimental data was unsuccessful (data not shown). Therefore, to identify the possible molecular determinants responsible for strong inhibition in the ELISA assay, we carried out molecular dynamics (MD) investigations on the docking-based complexes between PA and compounds 7g and 7f ( Figure   4 ). Indeed, these two molecules differ each other only for the -OH phenol group in 7g (L-Tyr residue) that is missing in 7f (L-Phe residue), but were notably different in the ELISA experiment, as 7g proved the most potent PA-PB1 inhibitor of the tested set while 7f was inactive up to 200 µM concentration. Thus, they represent a suitable model system to challenge MD simulations. The representative docking complex of 7g
and 7f was solvated in a box of water molecules and was energy minimized, heated and equilibrated in density as described previously, [83, 84] before to run 250 ns of unrestrained MD simulations. Cluster analysis performed on the whole MD production trajectories coupled with visual inspection clearly indicated that 7g is stable in the PB1 binding site, with a conformation that is highly consistent to that identified by molecular docking (Figure 5A) . The nitrile group of 7g establishes a H-bond interaction with the side chain of Lys643
(to allow comparison with results described in previous works [63, 71] [85] Delta energy calculations clearly showed that the different binding conformation is associated to a significantly different theoretical affinity, as reported in Table 2 , which suggests that ligand affinity is mainly related to enthalpy contributions. In summary, this molecular modeling investigation added further insights to the inhibition mechanism of tested molecules and might drive the design of ligands with enhanced affinity for PA. 
CONCLUSIONS.
In the frame of the limited armamentarium of drugs for the treatment of Flu infections together with the chemo-resistant phenotypes increasing, the search for novel antivirals with innovative mode of action became imperative. In recent years, the viral polymerase has proved to be an attractive target for drug design, although the current efforts led to quite toxic compounds. In particular, some research groups have been interested in the development of small molecules able to interfere with the correct assembly of RdRp complex, through the inhibition of the interaction between PA and PB1, two of its subunits. In this work, starting from previously published findings, a rational drug design led us to synthesize hybrid compounds characterized by the diphenyl-pyridine nucleus, identified as promising inhibitor of the above mentioned PPI, and the same last amino acids side chain of PB1N (Met-Asp-Val) in C2. Indeed, we planned the synthesis of the tri-peptidic (11), di-peptidic (Val-Asp, 9) and the mono-amino acid (Val, 7a) derivatives as methyl esters to ensure a higher passive membrane permeability. Biological data results highlighted a major anti-flu activity (EC50 in PRA) of 9 and 7a, not correlated to the low enzymatic inhibition (IC50 in ELISA). To better investigate this discrepancy, minireplicon experiments were performed, allowing us to confirm the PA-PB1 interaction disruption as the main target of our compounds. Moreover, we hypothesize that these methyl ester derivatives could be hydrolysed in cell, giving the corresponding free acids. In fact, the synthesized 10 and 8 (free acid dipeptide and mono-amino acid derivatives, respectively) showed a better IC50 when compared to that of 9 and 7a. Notably, valine derivatives 7a and 8 emerged as new hit compounds for further optimization. Aimed by the exploration of the chemical space around the C2 of the diphenyl-pyridine core, novel mono-amino acid derivatives (7b-h) were synthesized and tested. Interestingly, the modulation in C2 of the starting chemical structures led to an increase in the on-target activity. In particular, the best results were achieved with the isoleucine derivative (7c) that exhibited a good biological profile with no cytotoxic behaviour. Molecular modeling simulations added further insights to the inhibition mechanism of these compounds, showing that enthalpy contributions (i.e. H-bond interactions with PA key residues) are crucial to achieve strong PA-PB1
PPI inhibition in vitro. In summary, a new small library of hybrid derivatives endowed with anti-influenza activity was generated. Almost of all of these compounds were found to be not cytotoxic at high concentrations in the two cell lines used for testing and to inhibit actually the studied PPI. Moreover, we set up a quantitative four-step scaling-up procedure to synthesize the diphenyl-pyridine scaffold that might be helpful to expand the chemical class and to improve the inhibitory activity.
MATERIAL AND METHODS

COMPUTATIONAL SECTION
The crystallographic structure of Influenza A virus PA (C-terminal region) in complex with PB1N coded by PDB ID: 4WSB, [44] which was already validated as docking receptor in a previous work, [71] was used as rigid receptor in molecular docking studies. [26] Tested compounds were designed by means of Maestro their default values. MD simulations were carried out with Amber16, using the FF14SB force field for the protein and GAFF force field for small molecules. [86] Ligands partial charges were assigned at the am1-bcc level of theory. Each PA-ligand complex was solvated in a rectilinear box of TIP3P water molecules buffering 8 Å from the protein surface. Na + counter-ions were added to neutralize the total charge of the system. First, the water solvent was energy minimized for 500 steps with the steepest descent algorithm (SD) and 1500 steps with the conjugate gradient algorithm (CG); then, the whole system was energy minimized for 1000 steps SD and 4000 steps CG before to be heated up to 300 K in 100 ps (time-step is 2 fs). The heated system was equilibrated in density at constant pressure for 100 ps before to run an equilibration MD at constant pressure for 50 ns. Subsequently, unrestrained MD production was run for 250 ns at constant pressure. Analysis of MD trajectories, including cluster analysis, was carried out by cpptraj. [86] Graphics representations were drawn for clusters being representative of more than 60% of MD frames.
CHEMISTRY SECTION
All commercially available chemicals and solvents were used as purchased (Merck-Sigma Aldrich, Alfa-Aesar 
4-(4-Methylphenyl)-6-phenyl-2-sulfanyl-1,4-dihydropyridine-3-carbonitrile (13)
To a solution of sodium (186 mg, 8.10 mmol) in dry MeOH (22 mL 
4-(4-Methylphenyl)-6-phenyl-2-sulfanylpyridine-3-carbonitrile (14)
To a stirred solution of 13 (679 mg, 2.23 mmol) in DCM (15 mL), DDQ (1014 mg, 4.46 mmol) was added.
The mixture was stirred at room temperature for 3 h. The mixture was filtered and evaporated under reduced pressure. The dark solid obtained was decanted several times with MeOH, water and hexane to remove DDHQ.
The solid was then recrystallized from MeOH. TLC Rf (Hexane/AcOEt 4/1) 0. 
2-{[3-Cyano-4-(4-methylphenyl)-6-phenylpyridin-2-yl]sulfanyl}acetic acid (15)
To a stirred solution of 14 
Synthetic procedure for monoamino acid adducts (7a-h and 8)
General procedure for monoamino acid adducts (7a-h)
To a stirred solution of 15 ( 
Methyl (2S)-2-(2-{[3-cyano-4-(4-methylphenyl)-6-phenylpyridin-2-yl]sulfanyl}acetamido)-
3-methylbutanoate (L-Valine methyl ester adduct, 7a)
Eluted with Hexane/AcOEt 3/1. Yield: 20%. 
Methyl (2S)-2-(2-{[3-cyano-4-(4-methylphenyl)-6-phenylpyridin-2-yl]sulfanyl}acetamido)-
4-methylpentanoate (L-Leucine methyl ester adduct, 7b)
Eluted with AcOEt/ 
Methyl (2S,3S)-2-(2-{[3-cyano-4-(4-methylphenyl)-6-phenylpyridin-2yl]sulfanyl}acetamido)-3-methylpentanoate (L-Isoleucine methyl ester adduct, 7c)
Methyl (2S)-2-(2-{[3-cyano-4-(4-methylphenyl)-6-phenylpyridin-2-yl]sulfanyl}acetamido)-
3-(1H-imidazol-4-yl) propanoate (L-Histidine methyl ester adduct, 7d)
Methyl (2S)-3-carbamoyl-2-(2-{[3-cyano-4-(4-methylphenyl)-6-phenylpyridin-2yl]sulfanyl}acetamido) propanoate (L-Arginine methyl ester adduct, 7e)
Eluted with DCM/ 
Methyl (2S)-2-(2-{[3-cyano-4-(4-methylphenyl)-6-phenylpyridin-2-yl]sulfanyl}acetamido)-
3-phenylpropanoate (L-Phenylalanine methyl ester adduct, 7f)
Methyl (2S)-2-(2-{[3-cyano-4-(4-methylphenyl)-6-phenylpyridin-2-yl]sulfanyl}acetamido)-
3-(4-methoxyphenyl) propanoate (L-Tyrosine methyl ester adduct, 7g)
Eluted h at room temperature. The reaction was quenched with water and then it was extracted with AcOEt. The organic phase was washed with water, dried over Na2SO4, filtered and concentrated under reduced pressure.
The crude residue was purified through flash chromatography on silica gel. Eluted with Hexane/AcOEt 1/1. 
1,4-Dimethyl (2S)-2-[(2S)-2-amino-3-methylbutanamido]butanedioate (NH2-Val-Asp-
OMe(OMe), 17)
To a stirred solution of 16 (271 mg, 0.56 mmol) in DMF (7 mL), NaN3 (73 mg, 1.12 mmol) was added. The mixture was stirred at 50 °C for 12 h. The reaction was quenched with water and extracted with AcOEt. The organic phase was washed with water, dried over Na2SO4, filtered and concentrated under reduced pressure.
The crude residue was used in the next step without further purification. TLC Rf (Hexane/AcOEt 3/1) 0.57. 4-Dimethyl (2S)-2-[(2S)-2-(2-{[3-cyano-4-(4-methylphenyl) 
Methyl (2S)-2-[(2S)-2-[(2S)-2-amino-3-methylbutanamido]-4-methoxy-4oxobutanamido]-4-(methylsulfanyl) butanoate (Free amine tripeptide, 21)
Same deprotection protocol used for 17. To a stirred solution of 20 ( 
Tert-butyl (((3-cyano-6-phenyl-4-(p-tolyl)pyridin-2-yl)thio)methyl)carbamate (23)
To a stirred solution of compound 23 ( 
2-((3-cyano-6-phenyl-4-(p-tolyl)pyridin-2-yl)thio)acetamide (24)
To a stirred solution of 2-mercapto-pyridine 14 (120 mg, 0.40 mmol) in DMF (2 mL Avicel, and test compounds at the same concentrations was then added. After 2 days of incubation, cell monolayers were fixed with 4% formaldehyde and stained with 0.1% toluidine blue, and viral plaques were counted. Ribavirin and oseltamivir carboxylic acid were included in all experiments as reference compounds.
The mean plaque number obtained from the samples treated with DMSO was set at 100%.
Cytotoxicity Assay. Cytotoxicity of test compounds was assessed in MDCK and HEK 293T cells by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) method, as previously reported. [90, 91] Briefly, MDCK cells (5 × 10 3 cells/well on 96-well plates) and HEK 293T (2 × 10 4 cells/well on 96-well plates) cells were incubated with test compounds at 2-fold serial dilutions from 250 μM or DMSO. After 24 or 48 h for HEK 293T and MDCK cells, respectively, MTT solution (5 mg/mL in PBS) was added to each well, and plates were incubated for 4 h at 37 °C. Then, a solubilization solution was added to lyse cells. After 3 h of further incubation at 37 °C, absorbance was read at 620 nm using an ELISA plate reader (Tecan Sunrise).
Values obtained from the wells treated with only DMSO were used to set as 100% of viable cells. Ribavirin was included in all experiments as the reference compound.
Interference compound assessment.
The behaviour of all the tested compounds (7-11, 15, 23 and 24) as PAINS (Pan-Assay Interference Compounds) [93] was examined through prediction by the online FAFDrugs4 [94] [95] [96] (Free ADME-Tox Filtering Tool) program. Through its tool Bank-Formatter the compound library was prepared and then screened with the three different available filters A, B and C. All the analysed compounds resulted "accepted" by the software. [97] 
